CDKN2A and glioblastoma: Furthermore, in PBT003 GBM cell line, METTL3 or METTL14 knockdown led to upregulation of several oncogenes (e.g., ADAM19, EPHA3, and KLF 4) and downregulation of tumor suppressors (e.g., CDKN2A, BRCA2, and TP53I11), conversely, overexpression of METTL3 or treatment with FTO inhibitor MA2 resulted in reduced expression of these oncogenes [45].